CFO O. James Sterling resigns effective May 24; Joel R. Jung appointed interim CFO

Renalytix plc

CFO O. James Sterling resigned May 24, 2024; will remain through transition period ending June 10, 2024.
Board appointed Joel R. Jung as interim CFO effective May 28, 2024; Jung was previously CFO at Minerva Surgical (2020-2024).
CEO stated company is focused on cost reductions and commercial adoption of KidneyIntelX with FDA approval and reimbursement.
Resignation did not involve any disagreement with the company; Jung has no material interest in related-party transactions.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Joel R. Jung

Interim Chief Financial Officer

RNLXY · Renalytix plc

Effective: 2024-05-28
Filed: May 28, 2024, 7:59 PM ET

On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.

Departed

O. James Sterling

Chief Financial Officer

RNLXY · Renalytix plc

Effective: 2024-05-24
Successor: Joel R. Jung
Filed: May 28, 2024, 7:59 PM ET

On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

O. James Sterling resigned as Chief Financial Officer at Renalytix plc.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).

View on SEC.gov

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-24-064882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.